Dextran-Based Therapeutic Nanoparticles for Hepatic Drug Delivery

Foerster, Friedrich; Bamberger, Denise; Schupp, Jonathan; Weilbächer, Martin; Kaps, Leonard; Strobl, Stephanie; Radi, Lydia; Diken, Mustafa; Strand, Dennis; Tuettenberg, Andrea; Wich, Peter; Schuppan, Detlef

doi:10.2217/nnm-2016-0156

Cited by 56 publications

(21 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PEGylated dextran nanoparticles were almost cleared within 24 h after administration. Overall, PEGylated dextran nanoparticles showed potential for use in liver macrophage targeting [75]. A dextran nanoparticle with pH-dependent self-assembly manner was developed by Tang et al Folic acid was conjugated with dextran to yield the nanoparticle system.…”

Section: Dextran-based Nanoparticles For Cancer Therapymentioning

confidence: 99%

“…The nanoparticle formulation showed the highest tumor inhibition rate both in vitro and in vivo, and the survival time of murine breast carcinoma 4T1 cell subcutaneous tumor-bearing mice was prolonged as compared to free doxorubicin and folic acid blocked nanoparticle system [76]. PEGylated dextran, siRNA Changed biodistribution and cellular uptake without affecting cytotoxicity [75] Folic acid, doxorubicin Enhanced tumor inhibition; targeting folate receptors [76] 3.1.5. Albumin-Based Nanoparticles for Cancer Therapy Albumin is the protein-based natural ingredient most commonly used for cancer drug delivery (Table 2).…”

Section: Dextran-based Nanoparticles For Cancer Therapymentioning

confidence: 99%

See 1 more Smart Citation

Natural Ingredient-Based Polymeric Nanoparticles for Cancer Treatment

Wong

Chen

et al. 2020

Molecules

View full text Add to dashboard Cite

Cancer is a global health challenge. There are drawbacks to conventional chemotherapy such as poor bioavailability, development of drug resistance and severe side effects. Novel drug delivery system may be an alternative to optimize therapeutic effects. When such systems consist of natural materials, they offer important advantages: they are usually highly biocompatible, biodegradable, nontoxic and nonimmunogenic. Furthermore, natural materials can be easily modified for conjugation with a wide range of therapeutic agents and targeting ligands, according to the therapeutic purpose. This article reviews different natural ingredients and their applications in drug delivery systems for cancer therapy. Firstly, an overview of the polysaccharides and protein-based polymers that have been extensively investigated for drug delivery are described. Secondly, recent advances in using various natural ingredient-based polymeric nanoparticles for cancer therapy are reviewed. The characteristics of these delivery systems are summarized, followed by a discussion of future development and clinical potential. This review aims to summarize current knowledge and provide a basis for developing effective tailor-made formulations for cancer therapy in the future.

show abstract

Section: Dextran-based Nanoparticles For Cancer Therapymentioning

confidence: 99%

Section: Dextran-based Nanoparticles For Cancer Therapymentioning

confidence: 99%

Natural Ingredient-Based Polymeric Nanoparticles for Cancer Treatment

Wong

Chen

et al. 2020

Molecules

View full text Add to dashboard Cite

show abstract

“…Although some researchers intended to precisely target tumor or in ammation disease by respectively employing targeting motifs to recognize the speci c antigen or receptors on M1 [21][22][23] or M2 macrophages [24][25][26], the differentiating ability towards diseases has not been evaluated in these studies, and due to the in uence of a large number of phagocytes in the peripheral blood, such strategies do not seem reliable. For example, M2 macrophages express a large number of macrophage mannose receptor and scavenger receptor higher than M1 macrophages, but a few nanoparticles have been successfully targeted deliver to tumor and atherosclerosis in different studies [27][28][29][30][31], through modi cation with dextran, a speci c ligand of MMR and scavenger receptor [32].…”

Section: Introductionmentioning

confidence: 99%

The Double-edged Sword Effect of Macrophage Targeting Delivery System in Different Macrophage Subsets Related Diseases

Yuan

Long

Lin

et al. 2020

Preprint

View full text Add to dashboard Cite

Monocyte/macrophage targeting drug delivery system (MTDS) has been highly focused as an emerging routine for delivering drugs to various macrophage related diseases. However, the distinguishing ability towards different macrophage related diseases of these systems and the impact of them on macrophage function and disease progression have not been systematically revealed, which is significantly important for active targeting therapeutic or diagnostic strategies. Herein, taking dextran modified polystyrene nanoparticles (DEX-PS) as example, we demonstrate that modification by dextran can specifically enhance the recognition of nanoparticles (NPs) by M2 macrophages in vitro, however, which is obstructed by monocytes in peripheral blood proved by in vivo assays. DEX-PS is not only targeted distributed in tumor, a M2 macrophage related disease, but also highly distributed in M1 macrophages related disease, acute peritonitis. Additionally, DEX-PS play a double-edged role in these two different diseases by reeducating macrophages to pro-inflammatory phenotype. These results suggest that MTDS, even those designed based on the different expression of receptor on different macrophages subtypes, lacks distinguishing ability for different macrophage subsets related diseases in vivo. In addition to the potential impact of these carrier materials on the function of macrophages, in the study of MTDS, great attention should be paid to the distribution of nanoparticles in non-target diseases and the impact on its disease process.

show abstract

“…Dextran is a speci c ligand of macrophage mannose receptor (MMR) and scavenger receptor [31]. Both MMR and scavenger receptor are especially highly expressed on M2 macrophages, and lowly expressed on M1 macrophages, however, a puzzling phenomenon is that dextran were successfully employed as a targeting unit not only for targeting tumors, but also for in ammatory diseases [32][33][34][35][36]. Importantly, whether the speci c recognition of MMR on the surface of M2 macrophages by dextran cannot distinguish in ammation from tumor, as well as its mechanism and potential risks still unrevealed.…”

Section: Introductionmentioning

confidence: 99%

The Double-Edged Sword Effect of Macrophage Targeting Delivery System in Different Macrophage Subsets Related Diseases

Yuan

Long

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Monocyte/macrophage-targeting delivery systems (MTDSs) have been focused upon as an emerging routine for delivering drugs to treat various macrophage-related diseases. However, the ability of MTDSs to distinguish different macrophage-related diseases and their impact on macrophage function and disease progression have not been systematically revealed, which is important for actively targeted therapeutic or diagnostic strategies. Results: Herein, we used dextran-modified polystyrene nanoparticles (DEX-PS) to demonstrate that modification of nanoparticles by dextran can specifically enhance their recognition by M2 macrophages in vitro, but it is obstructed by monocytes in peripheral blood according to in vivo assays. DEX-PS not only targeted and became distributed in tumors, an M2 macrophage-related disease, but was also highly distributed in an M1 macrophage-related disease, namely acute peritonitis. Thus, DEX-PS acts as a double-edged sword in these two different diseases by reeducating macrophages to a pro-inflammatory phenotype. Conclusions: Our results suggest that MTDSs, even those designed based on differential expression of receptors on specific macrophage subtypes, lack the ability to distinguish different macrophage subtype-related diseases in vivo. In addition to the potential impact of these carrier materials on macrophage function, studies of MTDSs should pay greater attention to the distribution of nanoparticles in non-target macrophage-infiltrated disease sites and their impact on disease processes.

show abstract

Dextran-Based Therapeutic Nanoparticles for Hepatic Drug Delivery

Abstract: DNP are multifunctional liver-specific drug carriers which lack toxic side effects and may be utilized in clinical applications targeting liver macrophages.

Cited by 56 publications

References 21 publications

Natural Ingredient-Based Polymeric Nanoparticles for Cancer Treatment

Natural Ingredient-Based Polymeric Nanoparticles for Cancer Treatment

The Double-edged Sword Effect of Macrophage Targeting Delivery System in Different Macrophage Subsets Related Diseases

The Double-Edged Sword Effect of Macrophage Targeting Delivery System in Different Macrophage Subsets Related Diseases

Contact Info

Product

Resources

About